Mainz Biomed (NASDAQ:MYNZ – Get Free Report) shares traded down 3.7% during mid-day trading on Thursday . The stock traded as low as $4.22 and last traded at $4.33. 35,680 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 84,846 shares. The stock had previously closed at $4.50.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright downgraded shares of Mainz Biomed from a “buy” rating to a “neutral” rating in a research note on Monday, November 25th.
Read Our Latest Research Report on MYNZ
Mainz Biomed Stock Performance
Mainz Biomed Company Profile
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Read More
- Five stocks we like better than Mainz Biomed
- How to Plot Fibonacci Price Inflection Levels
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- What Are Dividend Achievers? An Introduction
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
